Introduction {#S1}
============

Head and neck squamous cell carcinoma (HNSCC) is one of the most common solid neoplasms worldwide. Its occurrence is being associated with exposure to smoking and alcohol consumption ([@B1]). Even though enormous progress concerning the treatment of HNSCC has been made, the mortality rates are still high due to local tumor invasion, development of metastases, and failure of chemo- and radiation therapies ([@B2]--[@B6]).

Various studies suggest an important role of the Wnt/β-catenin signaling pathway in human tumorigenesis of a number of malignancies, such as melanoma, ovarian cancer, and particularly colorectal cancer ([@B7]). Therefore, many proteins of this signaling pathway may serve as promising targets of therapeutic approaches.

In addition, several studies revealed the important role of the Wnt/β-catenin signaling pathway in the immunomodulation of antitumor responses, such as the development and regulation of T-lymphocytes at various stages of thymocyte differentiation. Correspondingly, several recent studies suggest an active role of the Wnt-regulator protein glycogen synthase kinase 3 (GSK-3) in different human cancers, either as a tumor suppressor or as a tumor promoter ([@B8]). In HNSCC, the prominent role of GSK-3 in the adenomatous polyposis coli (APC)--β-catenin destruction complex implies that an inhibition of GSK-3 could trigger tumor promotion by activating β-catenin. GSK-3 has, moreover, been shown to be a critical regulator of the nuclear factor (NF) kappaB activity ([@B9], [@B10]). The regulated inhibitory phosphorylation of Ser9GSK-3β is the main cause of WNT activation and has been shown to be upregulated in different epithelial cancers ([@B11]). Wnt signaling pathways have established importance in determining tissue development, differentiation, and embryogenesis as well as in tumor progression and invasiveness ([@B12], [@B13]). In colorectal cancer, inactivating mutations in the genes encoding APC or activating mutations of β-catenin result in β-catenin stabilization and tumor progression ([@B14]).

There are at least 19 identified Wnt homologs in humans, some of which have been identified as potential signaling molecules in different types of cancer ([@B15]). In patients with HNSCC, higher levels of active β-catenin have been shown to correlate with a bad prognosis, suggesting an inhibition of the Wnt/β-catenin cascade as a potential strategy for targeting HNSCC stem-like cells ([@B16]).

The monoterpenoid 1,8-cineol is the main component of the essential oil extracted from leaves of *Eucalyptus globulus*. Various biological activities have been attributed to 1,8-cineol, which is commonly applied to treat various chronic and acute inflammatory airway diseases as well as patients with polyposis nasi. Recently, it has been shown that 1,8-cineol leads to decreased activity of the pro-inflammatory NF-κB-signaling by inhibiting its nuclear translocation ([@B17], [@B18]).

Although positive respondings have been reported, the molecular mechanisms of its effect on the cellular progression and recurrence are still not fully understood.

In this work, we analyzed the influence of 1,8-cineol on the regulation of the Wnt/β-catenin signaling pathway in different permanent HNSCC cell lines.

Our data demonstrate for the first time that 1,8-cineol is able to inhibit the Wnt/β-catenin activity in HNSCC and leads to decreased expression levels of WNT11 and a decreased cellular progression and migration rate. Thus, our data indicate a new mechanism of 1,8-cineol activity and may lead to novel treatment approaches of this natural drug.

Materials and Methods {#S2}
=====================

Cells and Cell Culture Conditions {#S2-1}
---------------------------------

The adherent human head and neck squamous cell carcinoma cell lines, such as UT-SCC-16A, UT-SCC-16B, UT-SCC-60A, and UT-SCC-60B, were a generous gift from Reidar Grénmann (University of Turku, Finland). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM, 4.5 g/l [d]{.smallcaps}-glucose and [l]{.smallcaps}-glutamine) supplemented with 10% fetal bovine serum (both Life Technologies, Carlsbad, CA, USA), 1% sodium pyruvate (PAN-Biotech, Aidenbach, Germany), and 1% antibiotics (10,000 U/ml penicillin and 10,000 µg/ml streptomycin) (Biochrom, Berlin, Germany) at 37°C under 5% CO~2~ and 95% air atmosphere.

Antibodies {#S2-2}
----------

Anti-phospho-GSK-3α/β (Ser21/9) (\#9331), anti-GAPDH (\#2118), and β-tubulin (\#2146) were purchased from Cell Signaling Technology (Danvers, MA, USA). Both antibodies were used in a 1:1,000 dilution in TBS containing 3 or 5% BSA (PAA Laboratories, Pasching, Austria). Anti-phospho-GSK-3α/β (Y279/Y216) (\#ab68476) and anti-WNT11 (\#ab96730) were obtained from Abcam (Cambridge, UK) and used in a 1:1,000 and 1:3,000 dilution in TBS containing 3 or 5% BSA, too. Anti-active-β-catenin (\#05-665) was purchased from Merck Millipore (Billerica, MA, USA) and used in a 1:2,000 dilution in TBS and 3 or 5% BSA (Carl Roth, Karlsruhe, Germany).

Anti-Akt (\#9272), anti-Akt (Ser473) (\#9271), and anti-Akt (Thr308) (\#9275) were purchased from Cell Signaling (Billerica, MA, USA) and used in a 1:1,000 dilution in TBS and 3% BSA (Carl Roth, Karlsruhe, Germany). The species specific secondary antibodies anti-mouse IgG (whole molecule)-peroxidase (\#A9044) and anti-rabbit IgG (whole molecule)-peroxidase (\#A0545) were obtained from Sigma-Aldrich (St. Louis, MO, USA) and used in a 1:50,000 dilution in TBS containing either 5% BSA or 5% dry milk. Dead and apoptotic cells in response to 1,8-cineol were analyzed by annexin V and propidium iodide staining (Apoptosis Kit II; BD, Heidelberg, Germany).

Western Hybridization {#S2-3}
---------------------

Cells were washed twice in ice-cold PBS and then lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) containing aprotinin, pepstatin A, protease inhibitor cocktail, and phenylmethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, MO, USA) for 30 min. Three times 15 s ultrasoundbath was used to fragment the cells. Cellular debris were removed by centrifugation (13,000 rpm, 4°C, 10 min). Protein concentration was determined using Bradford assay with Quick Start™ Bradford 1× Dye Reagent (Bio-Rad Laboratories, Hercules, CA, USA). 4× SDS sample buffer was added, and the samples were boiled at 95°C for 5 min. Equivalent amounts of protein (30 µg) were separated by SDS-PAGE in a 10% polyacrylamide gel and transferred onto nitrocellulose membranes by tank blotting. For protein extraction from tissue, the tissue was initially homogenized with 500 µl RIPA buffer and protease inhibitors by using TissueLyser LT (Qiagen, Hilden, Germany) and then incubated and centrifugated as mentioned above.

The membranes were blocked with 0.1% TBS-T containing 5% BSA or 5% dry milk for 1 h at room temperature (RT) and then incubated with the primary antibodies overnight at 4°C. After washing with TBS and 0.1% TBS-T, the membranes were incubated with the species specific secondary antibody for 1 h at RT. The protein bands were visualized using Amersham™ ECL™ Primer Western Blotting Detection Reagent (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) and Fusion-FX7 as well as the corresponding software Fusion Bio-1D V12.14 (VilberLourmat, Eberhardzell, Germany), after extensive washing. The nitrocellulose membranes were re-probed overnight at 4°C with GAPDH antibody or β-tubulin antibody in order to determine the loading in each lane. The membranes were washed, incubated with secondary antibody and ECL detection reagent again.

PCR Array Human Epithelial to Mesenchymal Transition (EMT) {#S2-4}
----------------------------------------------------------

The human EMT RT^2^ Profiler™ PCR Array (Qiagen, Hilden, Germany) profiles the expression of 84 key genes that either change their expression during this process or regulate those gene expression changes. The array includes cell surface receptor, extracellular matrix, and cytoskeletal genes mediating cell adhesion, migration, motility, and morphogenesis; genes controlling cell differentiation, development, growth, and proliferation; as well as signal transduction and transcription factor genes that cause EMT and all of its associated processes.

Immunofluorescence {#S2-5}
------------------

An immunohistochemical method was used for the detection of GSK-3α/β (Ser21/9) within the tumor cells. Twenty-four hours prior to treatment with 100 µM cineol, the cells were seeded into 4-well chamber slides (Sarstedt AG; Numbrecht, Germany). After incubation, the medium was removed, and the cells were washed twice with PBS. For the intracellular staining, cells were permeabilized with 0.1% Triton-X-100 (Sigma-Aldrich Chemie GmbH, Steinheim) in PBS. The specific primary antibody anti-phospho-GSK-3α/β (Ser21/9) (\#9331) (Cell Signaling, Danvers, MA, USA) was diluted 1:50 with an antibody dilution buffer containing blocking buffer (DCS LabLine, DCS, Hamburg, Germany) and incubated in a humidified chamber for 1 h at RT. After washing with PBS, the secondary antibody goat anti-mouse FITC (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), diluted 1:100 was incubated for 45 min. The cells were rinsed three times in PBS. The nuclei were stained for 1 min using DAPI (1 µg/ml, Roche Diagnostics, Mannheim, Germany). The samples were rinsed three times for 5 min in PBS and were afterward embedded in Fluoromount G (Southern Biotechnologies Associates, Birmingham, AL, USA). Samples were evaluated under a 200 M microscope (Zeiss, Göttingen, Germany) by fluorescence microscopy (AHF Analysentechnik AG, Tübingen, Germany). Cells were photographed using an AxioCam MRm Rev.3 FireWire and the AxioVision Rel. 4.7 software (Zeiss, Jena, Germany).

1,8-Cineol {#S2-6}
----------

1,8-Cineol was used from Soledum^®^ capsules (Klosterfrau Healthcare Group, Cassella-med GmbH & Co. KG, Cologne, Germany). Native extract (0.6 mg/µl 1,8-cineol) was stored at 4°C, while stock solution was prepared by solving native extract in ethanol (100 mg/ml) followed by final diluting with DMEM high glucose (Biochrom, Berlin, Germany; 1 mg/ml).

MTT Assay {#S2-7}
---------

Cell proliferation was determined by a quantitative colorimetric *3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide*-*based* (MTT) cell assay. This assay determines viable cell numbers based on the mitochondrial conversion of MTT.

Around 5,000 cells were dispersed into each well of a 96-well plate. Twenty-four hours after culture, four different concentrations of 5-flourouracil or cisplatin were added to the cultures, or the cells were radiated at three doses. After 48 h, 10 µl of MTT dye (5 mg/ml) was added to each well. After 2 h of incubation with MTT, crystals were solubilized and gently shaken for 24 h at RT. The absorbance of the reduced formazan product in control and experimental wells was read using a multi-well ELISA reader at a wavelength of 570 and 690 nm. All growth samples of the MTT assay were carried out in triplicate.

*In Vitro* Scratch Assay {#S2-8}
------------------------

To analyze cellular *in vitro* migration by using a scratch assay, cells were seeded in cell culture chamber slides and incubated at 37°C under 5% CO~2~ and 95% air atmosphere. When they reached 100% confluence, a straight artificial gap was created in the middle of the chamber. In order to smooth the edges of the scratch and remove floating cells, the cells were washed with medium several times. Afterward the medium was removed and replaced by medium supplemented with 1,8-cineol. Untreated cells were used as negative control. Photographs of the migrating cells were taken every 15 min by a microscope (Keyence, Osaka, Japan) with stage incubator (Tokai Hit, Shizuoka, Japan) as well as multipoint and time lapse function.

Results {#S3}
=======

Dose-Dependent Inhibition of Proliferation of HNSCC by 1,8-Cineol {#S3-1}
-----------------------------------------------------------------

MTT assays were used in order to determine whether 1,8-cineol treatment led to the inhibition of the cellular viability of HNSCC. Concentrations of 1,8-cineol higher than 2 mM resulted in unsolicited strong effects on the cellular viability as well as on the cellular adherence (Figure [1](#F1){ref-type="fig"}A). Therefore, cell lines UT-SCC60A/B and UT-SCC16A/B were incubated with 1 and 2 mM 1,8-cineol for 240 h, respectively. These cell lines were chosen, since they revealed a prominent WNT/β-catenin signaling in earlier investigations in our group. A strongly decreased proliferation and dose-dependent cellular viability of the analyzed cell lines could be observed in response to treatment with 1,8-cineol (Figure [1](#F1){ref-type="fig"}B). To underline these data, the HNSCC cell line SCC16A was incubated with 1 and 2 mM 1,8-cineol, and after 24 h of incubation, the cells were harvested and stained with annexin and PI and analyzed by flow cytometry (Figure [1](#F1){ref-type="fig"}C). In order to carefully analyze the influence of 1,8-cineol on the molecular regulation of the Wnt/β-catenin signaling pathway in preferably vital cells, a maximum dose of 1 mM 1,8-cineol was used for the following investigations.

![**Dose-dependent reduction of the viability of HNSCC cell lines by 1,8-cineol**. MTT assays were used in order to determine the dose-dependent effects of 1,8-cineol treatment on the cellular viability of permanent HNSCC cell lines. **(A)** Permanent HNSCC cell lines 12A/B were incubated with different concentrations of 1, 1.5, 2, and 10 mM 1,8-cineol, respectively. **(B)** Clearly affected cell growth could as well be observed in the analyzed HNSCC cell 16A/B and 60A/B lines in response to an incubation with 1 and 2 mM 1,8-cineol, respectively. **(C)** HNSCC cell line SCC16A was incubated with 1 and 2 mM 1,8-cineol, and after 24 h of incubation, the cells were harvested and stained with annexin and PI and analyzed by flow cytometry, illustrating the decreased cellular viability in response to 1,8-cineol.](fonc-07-00092-g001){#F1}

Decreased β-Catenin Activity in Response to 1,8-Cineol Treatment {#S3-2}
----------------------------------------------------------------

In order to investigate the influence of 1,8-cineol on the activity and regulation of the Wnt/β-catenin signaling cascade, we first analyzed the expression level of active β-catenin, which is the central transcriptional activator protein of this pathway. Our data revealed a strong decrease of active β-catenin in response to 24 h incubation with already 100 µM 1,8-cineol in the analyzed HNSCC cell lines 60B, 16A, and 16B compared to the medium controls, whereas active β-catenin expression was only weakly effected in cell line 60A. These data were corroborated using immunofluorescence staining of β-catenin, indicating an inhibition of the Wnt/β-catenin signaling pathway in HNSCC due to 1,8-cineol treatment (Figure [2](#F2){ref-type="fig"}).

![**Expression of active β-catenin and P-glycogen synthase kinase 3 (GSK-3) (Ser9/21) in response to cineol**. Western blot analysis of the whole cell proteins was used to demonstrate the effect of 24 h treatment with 100 µM 1,8-cineol on the protein expression levels of **(A)** phospho-GSK-3 (Ser9/21), **(B)** phospho-GSK-3 (Tyr279/216), and **(C)** active β-catenin, in permanent HNSCC cell lines 60A/B and 16A/B. β-Tubulin was used as a loading control. **(D)** Immunofluorescence staining of active β-catenin in response to 24 h treatment with 100 µM 1,8-cineol. DAPI staining was used to visualize the cell nuclei.](fonc-07-00092-g002){#F2}

GSK-3 Regulation in Response to 1,8-Cineol {#S3-3}
------------------------------------------

To further define the inhibition of the WNT pathway in response to 1,8-cineol, additional investigations were carried out to analyze the corresponding phosphorylation levels of the β-catenin regulator GSK-3. GSK-3 is a constitutively active protein kinase and is inhibited by phosphorylation of GSK-3 on Ser-21 (GSK-3α) or Ser-9 (GSK-3β). Western hybridization experiments were performed to study the expression and phosphorylation levels of GSK-3α/β in the absence and presence of 100 µM 1,8-cineol.

Our data clearly indicate that 1,8-cineol leads to decreased levels of phosphorylated GSK-3α/β (Ser-9/21), which consequently leads to an increased activity of GSK-3 and thus to an increased degradation of β-catenin in the analyzed cell lines (Figure [2](#F2){ref-type="fig"}B). Phosphorylation of tyrosine-279 in GSK-3α and tyrosine-216 in GSK-3β leads to an enhanced GSK-3 activity. As shown in Figure [1](#F1){ref-type="fig"}C, expression levels of GSK-3α/β (Tyr-279/216) were not markedly effected by 1,8-cineol (Figure [2](#F2){ref-type="fig"}C).

Decreased Endolysosomal Localization of GSK-3 (Ser9/21) {#S3-4}
-------------------------------------------------------

In addition to its phosphorylation at Ser9/21, GSK-3 activity is also regulated on the level of its subcellular localization. In order to decrease its kinase activity, GSK-3 can be translocated in endolysosomal vesicles to be separated from its substrates. Our immunohistochemical investigations demonstrate a decreased expression as well as a decreased endolysosomal localization of GSK-3 (Ser9/21) in cell lines UT-SCC60A/B and UT-SCC16A/B in response to 100 µM 1,8-cineol, which underlines its decreased inhibition after 1,8-cineol treatment (Figure [3](#F3){ref-type="fig"}).

![**Subcellular localization of P-synthase kinase 3 (GSK-3) (Ser9/21) in response to cineol**. Immunohistochemical investigations demonstrate a decreased expression and endolysosomal localization of phospho-GSK-3 (Ser9/21) in HNSCC cell lines 60A/B **(A)** and 16A/B **(B)** in response to 100 µM 1,8-cineol compared to the medium control. Nuclei were stained using DAPI.](fonc-07-00092-g003){#F3}

AKT, a Negative Regulator of GSK-3, Is Not Effected by 1,8-Cineol {#S3-5}
-----------------------------------------------------------------

Glycogen synthase kinase 3 is involved in the regulation of various biosynthetic pathways, and various kinases are able to regulate the GSK-3 activity *via* phosphorylation at its activating or inhibiting phosphorylation sites. Akt kinase (also known as PKB) was identified as an oncogene with serine/threonine kinase activity and was shown to be a negative regulator of GSK-3β activity *in vivo* ([@B19], [@B20]). Akt is activated by phospholipid binding and activation loop phosphorylation at Ser473 and Thr308 by PDK1 ([@B21]). Therefore, in a first approach, we analyzed the expression and phosphorylation levels of Akt in response to 100 µM 1,8-cineol. Neither the expression nor the Ser473 and Thr308 phosphorylation levels of Akt were markedly effected in all analyzed cell lines (Figure [4](#F4){ref-type="fig"}).

![**Expression of Akt, P-Akt (Thr308), and P-Akt (Ser473) in response to 1,8-cineol**. Western blot analysis of the whole cell proteins was used to demonstrate the effect of 100 µM 1,8-cineol on the protein expression levels of Akt, P-Akt (Thr308), and P-Akt (Ser473) in permanent HNSCC cell lines 60A/B and 16A/B. β-Tubulin was used as a loading control.](fonc-07-00092-g004){#F4}

Decreased Wnt 11 Expression in Response to 1,8-Cineol {#S3-6}
-----------------------------------------------------

Since Wnt/β-catenin signaling is well known to be involved in the regulation of the EMT ([@B22]), we investigated the transcriptional profiles of various EMT related genes in response to 1,8-cineol. Therefore, we used the PCR-based "RT^2^ EMT Profiler," which allows the comprehensive analyses of 84 different EMT-related genes. The received data revealed strongly decreased mRNA levels of Wnt11 in response to 100 µM 1,8-cineol in the analyzed HNSCC cell lines.

In order to corroborate this highly interesting finding on the protein level, four different HNSCC cell lines were analyzed *via* Western hybridization experiments using a specific anti-Wnt11 antibody. Protein expression of Wnt11 was found to be decreased in response to 1,8-cineol in a dose-dependent manner. All analyzed permanent HNSCC cell lines except cell line UT-SCC 16B showed a strong downregulation of WNT11 expression in response to 24 h treatment with 1 µM cineol (Figure [5](#F5){ref-type="fig"}). WNT11 has been shown to stimulate the proliferation and migration activity of cancer cells ([@B23]). Thus, scratch assay analyses were carried out, which is affected by both proliferation and cellular migration activity. Our data revealed a dose-dependent decreased migration/proliferation rate of the analyzed cell lines in response to 1,8-cineol in cell lines UT-SCC 60A/B and UT-SCC 16A. UT-SCC 16B showed an unaffected migration rate correspondingly to the observed unaffected WNT11 expression in response to 1,8-cineol (Figure [6](#F6){ref-type="fig"}).

![**Expression of WNT11 in response to cineol**. Expression levels of WNT11 were investigated on the **(A)** mRNA as well as on the **(B)** protein level using the RT^2^-PCR Profiler and Western hybridization experiments, respectively. Western blot analysis of the whole cell proteins was used to demonstrate the effect of 1,8-cineol on the protein expression levels in permanent HNSCC cell lines 60A/B and 16A/B. β-Tubulin was used as a loading control.](fonc-07-00092-g005){#F5}

![**Decreased migration rate in response to 1,8-cineol**. Scratch assay analyses were carried out, which revealed a decreased migration rate of the analyzed cell lines UT-SCC-16A/B (**A**) and UT-SCC 60A, whereas cell line UT-SCC 60B was not inhibited in response to 1,8-cineol (**B**).](fonc-07-00092-g006){#F6}

Discussion {#S4}
==========

The monoterpene oxide 1,8-cineol resembles the natural plant-derived component of the clinically approved drug Soledum, which is applied for the therapy of airway diseases, such as chronic sinusitis, bronchitis or asthma.

1,8-Cineol has been used as an antibacterial ([@B24]) and anti-inflammatory ([@B25], [@B26]) agent. Although clinical trials underline the beneficial effects of 1,8-cineol in treating different types of diseases, the underlying molecular mechanisms remain unclear.

Here, we show that 1,8-cineol is capable to inhibit proliferation of permanent cell lines of head and neck cancer (HNSCC) in a dose-dependent way. These data go along with previously demonstrated antitumor effects against colon cancer, where doses of 1,8-cineol between 5 and 50 mM were used ([@B27]). In this work, we used a maximum dose of 1 mM 1,8-cineol in order to carefully analyze the molecular regulation of the Wnt/β-catenin signaling pathway in response to this natural drug in preferably unaffected cells.

One of the major pathways for cell proliferation, dedifferentiation, the immunological structure of the tumor-microenvironment equilibrium and EMT in HNSCC is the WNT pathway. Exposure of HNSCC cell lines to 1,8-cineol leads to specific downregulation of GSK-3α/β (Ser-9/21), a central switch in this pathway. 1,8-Cineol acts specifically, as expression levels of GSK-3α/β (Tyr-279/216) were not markedly affected. In HNSCC, the prominent role of GSK-3 in the APC--β-catenin destruction complex implies that an inhibition of GSK-3 could trigger tumor promotion by activating β-catenin. The regulated inhibitory phosphorylation of Ser9GSK-3β is the main cause of WNT activation and has been shown to be unregulated in different epithelial cancers ([@B11]). The downregulation of GSK-3α/β (Ser-9/21) through 1,8-cineol inhibits the inhibitor of this pathway leading to increased activity of GSK-3 and thus to downregulation of active β-catenin, actively blocking the transnuclear signaling of the WNT pathway.

In addition to its phosphorylation at Ser9/21, GSK-3 activity is also regulated on the level of its subcellular localization. In order to decrease its kinase activity, GSK-3 can be translocated in endolysosomal vesicles to be separated from its substrates ([@B28]). Our immunohistochemical investigations demonstrate a decreased expression as well as a decreased endolysosomal localization of GSK-3 (Ser9/21) in cell lines UT-SCC60A/B and UT-SCC16A/B in response to 100 µM 1,8-cineol, which underlines its decreased inhibition after 1,8-cineol treatment.

Glycogen synthase kinase 3 is involved in the regulation of various biosynthetic pathways, and various kinases are able to regulate the GSK-3 activity *via* phosphorylation at its activating or inhibiting phosphorylation sites. Akt kinase (also known as PKB) was identified as an oncogene with serine/threonine kinase activity and was shown to be a negative regulator of GSK-3β activity *in vivo* ([@B19], [@B20]). As GSK-3 (Ser9/21) is actively regulated by 1,8-cineol, we attempted to exclude a loop influence on AKT signaling, which we could exclude on the protein level. Various additional cell signaling pathways are known to be involved in the regulation of GSK-3 activity, such as the Wnt-signaling pathway and the MAPK pathway, which may be effected by 1,8-cineol treatment. Traditionally, Wnt signals have been classified into two types, namely, the canonical (β-catenin dependent) and non-canonical (β-catenin independent), respectively. This classification was based on the biological activity, where canonical Wnts (e.g., Wnts 1 and 3a) induced the formation of a secondary axis formation in *Xenopus laevis* embryos and non-canonical Wnts (e.g., Wnts 4, 5a, and 11) did not ([@B29]). In fact, Wnt signaling is more complex and known to be context dependent. There are multiple intracellular regulatory cascades, some of which are composed of both canonical and non-canonical components ([@B12], [@B30]).

Dwyer et al. have shown that silencing of β-catenin expression strongly reduced the migratory capacity of breast, prostate, and colon cancer cells *in vitro*. The migratory activity could be attributed to the β-catenin-dependent induction of WNT11, which was shown to be an autocrine regulatory loop. Investigations using conditioned medium harboring recombinant WNT11 identified this protein as the key mediator of migratory activities ([@B31]). Our experiments reveal that 1,8-cineol is not only capable to reduce the expression of β-catenin but also of WNT11 in permanent HNSCC cell lines on the transcriptional and protein level. Correspondingly, our data indicate that a decreased expression of WNT11 in response to 1,8-cineol is accompanied with decreased migration rates. In intestinal epithelial cells, it was shown that Wnt11 promotes proliferation and migration by a β-catenin-independent mechanism, which suggests that β-catenin is required for the transcriptional activation of Wnt11 but not for the later cellular activities of the Wnt11 protein ([@B32]). Recently, it has been shown that Wnt11 and Wnt5a are capable to inhibit the canonical Wnt pathway *via* a caspase-dependent degradation of AKT ([@B33]). Furthermore, gain- and loss-of-function approaches revealed that WNT11 is able to induce an increased activity of matrix metalloproteinase-2 and -9 ([@B23]).

To date, 1,8-cineol has been applied to cancer cells already with asthonishingly good results as it was reported to induce apoptosis in leukemia cell lines ([@B34]) and colorectal cancer ([@B27]). Greiner et al. have demonstrated that 1,8-cineol inhibits the nuclear import of the transcriptional activator protein NF-κB p65 and correspondingly its transcriptional activity ([@B18]) leading to decreased cell proliferation. Our findings of the suppressive influence of 1,8-cineol on relevant components in the WNT pathway-driven cancer progression, such as GSK-3 (Ser 9/21), β-catenin, and WNT11, describe a completely novel mode of action, which may lead to novel treatment approaches of this natural drug.
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